Novartis Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 150 projects in clinical development. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2020.

  • AAA601 (177Lu-dotatate)
    Lutathera®
    Oncology Phase 3 Radioligand therapy target SSTR
    New Indication
  • AAA603
    177Lu-NeoB
    Oncology Phase 1 Radioligand therapy target GRPR
    Lead Indication
  • AAA617
    177Lu-PSMA-617
    Oncology Phase 3 Radioligand therapy target PSMA
    New Indication
  • AAA617
    177Lu-PSMA-617
    Oncology Registration Radioligand therapy target PSMA
    Lead Indication
  • AAA617
    177Lu-PSMA-617
    Oncology Phase 3 Radioligand therapy target PSMA
    New Indication
  • ABL001
    asciminib
    Oncology Phase 3 BCR-ABL inhibitor
    New Indication
  • ACZ885
    canakinumab
    Oncology Phase 3 IL-1b Inhibitor (Anti-interleukin-1ß monoclonal antibody)
    New Indication
  • ADPT03
    ADPT03
    Oncology Phase 1 BCL11A
    Lead Indication
  • ABL001
    asciminib
    Oncology Registration BCR-ABL inhibitor
    Lead Indication
  • AIN457
    Cosentyx®
    Immunology, Hepatology and Dermatology Phase 3 IL17A Inhibitor (Anti-interleukin-17 monoclonal antibody)
    Supplementary Indication

Legend

 

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

 

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.